RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
WuXi AppTec, China’s largest CRO/CMO, acquired San Diego’s Pharmapace, a clinical research service company offering biometrics services for all phases of clinical trials, regulatory submissions and post marketing support. Pharmapace will become a wholly-owned subsidiary of WuXi Clinical, the clinical CRO arm of WuXi AppTec. Founded in 2013, Pharmapace will focus on increasing its core biometrics competences while it integrates with WuXi Clinical’s other clinical development services. Financial details were not disclosed.
Source: China Biotoday
